Environmental

Sustainable Vaccine Manufacturing: Valneva leverages established inactivated vaccine platforms, which are generally associated with lower environmental risk profiles compared to live or recombinant technologies, and has demonstrated the ability to scale production for global health needs without major reported environmental incidents.

Product Portfolio Targets Unmet Needs: The company’s focus on vaccines for diseases such as Lyme, Zika, and Japanese encephalitis addresses global health threats, supporting positive environmental and public health outcomes by reducing disease burden and associated resource use.

R&D Investment in Emerging Infectious Diseases: Valneva’s significant R&D spend (39% of revenue) is directed toward innovative vaccines for emerging diseases, which can contribute to long-term sustainability by preventing outbreaks and reducing the need for resource-intensive emergency responses.

Valneva’s environmental profile is strong, driven by its focus on sustainable vaccine manufacturing and R&D targeting global health threats. The company’s approach supports both public health and environmental sustainability, with no material environmental controversies reported.

Social

Product Safety and Regulatory Scrutiny: Recent safety concerns regarding the IXCHIQ chikungunya vaccine, including CDC and FDA actions, have led to regulatory investigations and ADR price declines, highlighting ongoing product safety and reputational risks.

Workforce and Stakeholder Engagement: Valneva maintains a specialized workforce focused on vaccine R&D and manufacturing, with no major reported labor disputes or controversies, but limited public disclosure on diversity, equity, and inclusion initiatives.

Access to Medicines and Global Health Impact: The company’s portfolio addresses diseases with unmet medical needs, and partnerships (e.g., with Pfizer for Lyme disease) aim to expand access, though commercial focus on travel vaccines may limit broad public health reach.

Valneva’s social performance is moderate, reflecting its positive impact on global health through vaccine innovation but tempered by recent product safety issues and limited transparency on workforce and community practices.

Governance

Board and Leadership Structure: Valneva’s board includes experienced executives and independent directors, but recent regulatory and legal challenges raise questions about risk oversight and crisis management effectiveness.

Transparency and Investor Communication: The company regularly engages with institutional investors and provides detailed financial and pipeline updates, but ongoing securities fraud investigations may impact perceived governance quality.

Financial Discipline and Capital Allocation: Valneva has improved its financial flexibility through debt refinancing and reduced cash burn, but persistent net losses and high R&D intensity signal execution risk and reliance on external funding.

Valneva’s governance is moderate, with strengths in board experience and investor communication offset by regulatory scrutiny, legal investigations, and ongoing financial execution risks.

Overall Score

Valneva demonstrates strong environmental stewardship and a positive social mission through vaccine innovation, but its overall ESG profile is constrained by recent product safety controversies, regulatory investigations, and moderate governance practices. The company’s long-term ESG trajectory will depend on its ability to address safety concerns, strengthen risk oversight, and deliver on its pipeline while maintaining financial discipline.